Glofitamab
Availability of ACE Drug Guidance
Yes
Biologics Drug Information Overview
Yes
Post-marketing information
Patient Alert Card
Subsidy Information and Financing Scheme
No
Active ingredient: Glofitamab
General information
Subsidy Information and Financing Scheme
Not Applicable
Drug Guidance for Subsidy
The Ministry of Health’s Drug Advisory Committee has recommended:
Glofitamab 2.5 mg and 10 mg concentrate for solution for infusion, for use in combination with gemcitabine and oxaliplatin, for relapsed or refractory diffuse large B-cell lymphoma not otherwise specified in patients who are not candidates for autologous stem cell transplant.
Funding status
[R] Glofitamab 2.5 mg and 10 mg concentrate for solution for infusion are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication from 1 September 2026.
Clinical indication, subsidy class and MediShield Life claims eligibility for glofitamab are provided in the Annex.
[NR] The Ministry of Health’s Drug Advisory Committee has not recommended glofitamab for inclusion on the MOH List of Subsidised Drugs for treating relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The decision was based on uncertain clinical effectiveness and unfavourable cost effectiveness of glofitamab compared with relevant comparators, and the unacceptable price-volume agreement proposed by the company.
Clinical indication, subsidy class and MediShield Life claim limit for glofitamab are provided in the Annex.